Source: Myeloma – Hematology Advisor
Circulating tumor cell levels were an independent predictor of progression-free survival and overall survival.
Read More
Recent Content
- Dr Jagannath on the Potential Role for Linvoseltamab in R/R Multiple Myeloma
- Decreasing Grade 3/4 Infections, Limited Hospitalizations Underscore Potential for Linvoseltamab in R/R Myeloma
- ODAC Decisions Confirm Benefit of Ide-Cel and Cilta-Cel in Earlier Line R/R Myeloma Therapy
- Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1
- Real-World Registry on the Pharmacotherapy of Multiple Myeloma and Associated Renal and Pulmonary Impairments in the Greater Gulf Region: Protocol for a Retrospective Real-World Data Study
- Cytomegalovirus Reactivation During Elotuzumab Therapy in Patients with Multiple Myeloma
- Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial
- Unique cutaneous metastasis of multiple myeloma
- Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives
- Clinical Efficacy and Safety of Ixazomib-Containing Regimens in the Treatment of Patients with Multiple Myeloma